 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Verastem
VSTM
conference date: November 6, 2024 press release only
Verastem Cancer Therapy Should Get Traction, Raise Stock Price March 23, 2019 at Seeking Alpha
Verastem (VSTM) is a commercial-stage biotechnology company specializing in cancer therapies.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| CLDX |
| CLSN |
| EPZM |
| GILD |
| GLYC |
| ILMN |
| INCY |
| INO |
| ISRG |
| MCHP |
| PLX |
| REGN |
| RNA |
| SAGE |
| SANA |
| SYRS |
| TSVT |
| VBLT |
| VRTX |
| XLRN |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2022 William P. Meyers